| Recruiting | Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC NCT06681220 | VA Office of Research and Development | Phase 1 / Phase 2 |
| Unknown | The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell L NCT05162196 | Wuhan University | Phase 2 |
| Terminated | Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC NCT04610658 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Unknown | Anlotinib in Treatment of Recurrent Small Cell Lung Cancer NCT03732846 | Peking University Cancer Hospital & Institute | Phase 2 |
| Completed | Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients NCT01999881 | University of Wisconsin, Madison | N/A |
| Completed | CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer NCT01931787 | Wake Forest University Health Sciences | Phase 1 |
| Completed | Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers NCT01935336 | University of Colorado, Denver | Phase 2 |
| Completed | Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer NCT01901653 | Stemcentrx | Phase 1 / Phase 2 |
| Terminated | Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent NCT01803269 | University of Chicago | Phase 2 |
| Withdrawn | Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body NCT01325753 | Wake Forest University Health Sciences | N/A |
| Completed | Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer NCT01457469 | Wake Forest University Health Sciences | Phase 1 |
| Completed | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors NCT01155258 | University of Southern California | Phase 1 |
| Completed | S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer NCT00828139 | National Cancer Institute (NCI) | Phase 2 |
| Completed | R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer NCT00773955 | National Cancer Institute (NCI) | Phase 2 |
| Completed | AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer NCT00528645 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lun NCT00521144 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer NCT00470054 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer NCT00182689 | National Cancer Institute (NCI) | Phase 2 |
| Completed | 7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell NCT00098956 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or NCT00088933 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer NCT00086827 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Ce NCT00084487 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung Cancer NCT00052949 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Ce NCT00042978 | National Cancer Institute (NCI) | Phase 2 |
| Completed | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid NCT00031681 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors NCT00028535 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC) NCT00168922 | Charite University, Berlin, Germany | Phase 2 |
| Completed | FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Can NCT00020202 | National Cancer Institute (NCI) | Phase 2 |